Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effectsAlexandria P. Eiken(University of Nebraska Medical Center), Dalia El‐Gamal(University of Nebraska Medical Center)bioRxiv (Cold Spring Harbor Laboratory)February 3, 202410.1101/2024.01.31.578283Cited by 0SaveCiteExport RISWatch citationsRelated PapersBromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro|Biomedicines|2021|30The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax|Hemato|2024|2